Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, November 27, 2014
Technology Networks
 
Register | Sign in
Home Page>Posters

  Posters

HOMOGENEOUS ADCs BEARING TWO DIFFERENT PAYLOADS SHOW STRONG SYNERGY IN TUMOR KILLING
Lisha Allen, Yi Mi, Muhammad Abbas, Wolfgang Richter, and Sean Hu

We presented a one-pot reaction to prepare site-specific ADCs using available mABs on hand without re-engineering. We have identified a novel non-cleavable linker, which increases not only ADC stability, but also potency. We also demonstrate synergy in cancer cell killing of hybrid ADC loaded with two different toxins

More information
Enabling Epigenetics Studies from HTS to SAR : A Novel HTRF® Platform to Identify and Characterize Reader Domain Inhibitors
T. Roux1, M. Badol1, N. Douayry1, L. Sergeant1, E.Trinquet1, F. Degorce1, S. Milhas2, S. Betzi2, C. Derviaux2, C. Eydoux3, J. Letienne2, A. Lugari2, Y. Collette2, J-C. Guillemot3 et X. Morelli2

Discover a novel HTRF platform to identify and characterize the vast variety of epigenetic binding domain.

More information
Next Generation Multivalent PRINT Nanoparticle Vaccine Targeting Pneumococcal Disease
Shyam Rele,1 RiLee Robeson,1 Anton Beletskii,1 Jeremy Hansen,1 Meredith Earl,1 Gabe Fawcett,1* Marquita Lilly,1 Joseph Marchand,1 Michele Stone,1 Camille Bernasconi,1 Jinny Conley,1 Michael Hunter,1 Ramya Yadavalli,1 Nicole Meyer,1 Lara Kelly,1 Ben Yerxa,1 Jeff Maisonneuve,2 Mark Alderson,2 Frank Malinoski1

A new generation PRINT nanoparticle Pneumococcal vaccine matrix has been designed to mimic size and structural aspects of bacterial pathogens to efficiently present and deliver polysaccharide and protein antigens to elicit robust immune responses.

More information
Print Nanoparticle Vaccine Carrying Bacterial Polysaccharide And Protein Antigens Induces Enhanced B- And T-Cell (Il-17) Immunity
Anton Beletskii,1 Camille Bernasconi,1 Jinny Conley, Meredith Earl,1 Gabe Fawcett,1 Jeremy Hansen,1 Lara Kelly,1 Marquita Lilly,1 Frank Malinoski,1 Joseph Marchand,1 Nicole Meyer,1 Shyam Rele,1 RiLee Robeson,1 Michele Stone,1 Ben Yerxa,1 Jeff Maisonneuve,2 Mark Alderson 2

Antigenic multivalent PRINT nanoparticle formulations leverage precise control of size, shape and composition, sterile filterability and scalable cGMP roll-to roll manufacturing to offering a low cost and simplified manufacturing advantage over traditional conjugate vaccines.

More information
Significant Increase of Sensitivity on Rapid Influenza Antigen Assays Using Silver Amplification Immunochromatography.
Satoshi KIMURA1), Hideyoshi OHTO2), Hayato YAMAGUCHI1), Seiji FUKUOKA1), Emiko NAKAMA1), Akiko TERADA3), and Yoh UMEDA2)

We have developed a new rapid bed-side assay system for in vitro diagnosis of infectious diseases, using “silver amplification method”, an application of photography-developing technology. The automatic analyzer brings results in fifteen minutes, enhancing sensitivity up to 1000 times compared to the conventional immunochromatography. We applied the technology for diagnosis of hospitalized children. The analyzer was useful for rapid and precise diagnosis of influenza A and B.

More information
Developing Functional Monoclonal Antibodies for Beta-3 Adrenergic Receptor
Miao Tan and Helena Mancebo

Our preliminary data showed that several mAb clones specifically bound to the receptor while increasing the receptor function by acting as agonists.

More information
Early Immunogenicity Risk Mitigation
Chloé Ackaert, Brecht Hoedemaekers, Sofie Pattijn and Philippe Stas

The ability of a drug candidate to induce an unwanted immune response can be a significant hurdle during drug development and a reason for product failures. Unwanted immunogenicity can cause loss of efficacy, altered pharmacodynamics and stability problems. .

More information
MAB Discovery Technology: A Smart Way to Highly Diverse and Functional Therapeutic Antibodies
Hans-Willi Krell

MAB Discovery GmbH developped a highly integrated process which provides diverse antibodies by starting with a high number of B cells and filtering the relevant antibodies by an early-on functional screening.

More information
PRESEPSIN, A SOLUBLE CD14-SUBTYPE, A POSSIBLE NEW BIOMARKER INCREASES IN SEPTIC PATIENTS’ PLASMA FROM PEDIATRIC DEPARTMENT.
Hayato YAMAGUCHI1), Satoshi KIMURA1), Seiji FUKUOKA1), Emiko NAKAMA1), Hideyasu OTO2), Makoto INOUE2), Takashi SOGA2), Shigetaka KITAZAWA2), Yoh UMEDA2)

Increased plasma concentration of soluble CD14-subtype (presepsin) was observed in pediatric patients with bacteremia. Presepsin could be a possible biomarker of sepsis in pediatric patients, however, their reference interval in children could be lower than that of adults. More studies with larger number of samples are required to confirm the result.

More information
A Rapid and Effective Tool for Monitoring Monoclonal Antibody Production
B. Bhullar, Ph.D., Carlina Hui, B.Sc., M. Hariharan, M.Sc., J. Hewitt, B.Sc , and N. Vats, Ph.D.

Monoclonal antibodies (Mab) are used in a variety of fields from diagnostics to therapeutics. Manufacturers of in vitro diagnostics (IVD) commonly use third-party suppliers to meet their needs for specified monoclonal antibodies.

More information
<< 1 2 3 >>
Showing Results 1 - 10 of 29
Scientific News
New Study Reveals Why Some People May be Immune to HIV-1
Natural genetic variation in a protective antiviral enzyme holds promise for new therapies.
Monitoring Effectiveness Of Hay Fever Immunotherapy
A new test for measuring histamine release from certain white blood cells could help doctors monitor the effectiveness of immunotherapy for hay fever.
Precisely Off The Mark
Possible cause discovered for failure of targeted liver cancer therapies.
Researchers Tease Out Glitches in Immune System's Self-Recognition
A new study revises understanding of how the process works and sheds light on autoimmune disease.
Breakthrough in Managing Yellow Fever Disease
UC Riverside-led research could lead to antiviral therapeutics and better diagnostics to prevent spread of potentially fatal viral infection.
Anti-Leukemia Drug May Also Work Against Ovarian Cancer
An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia (CLL) may also prove effective against ovarian cancer – and likely other cancers as well.
New Tools in Fight Against Virus that Attacks the Brain
Researchers have developed new insight into a rare but deadly brain infection, called progressive multifocal leukoencephalopathy (PML).
Novel Cancer Vaccine Approach for Brain Tumors
Researchers unravel the mechanisms behind a novel cancer vaccine for brain tumors, paving the way for further development.
Immune System Surprise Hints at New Strategy for Fighting HIV
Surprising twist may open a new avenue in the fight.
Preventing and Curing Rotavirus Infection
Rotavirus infection could be prevented and cured by activating the innate immune system with flagellin.
Skyscraper Banner
SELECTBIO Market Reports
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv